- Home
- RCKY vs AARD Comparison
RCKY vs AARD Comparison
Compare RCKY & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCKY
- AARD
- Stock Information
- Founded
- RCKY 1932
- AARD 2017
- Country
- RCKY United States
- AARD United States
- Employees
- RCKY N/A
- AARD N/A
- Industry
- RCKY Shoe Manufacturing
- AARD Biotechnology: Pharmaceutical Preparations
- Sector
- RCKY Consumer Discretionary
- AARD Health Care
- Exchange
- RCKY Nasdaq
- AARD Nasdaq
- Market Cap
- RCKY 174.1M
- AARD 271.1M
- IPO Year
- RCKY 1993
- AARD 2025
- Fundamental
- Price
- RCKY $27.83
- AARD $12.57
- Analyst Decision
- RCKY Hold
- AARD Strong Buy
- Analyst Count
- RCKY 1
- AARD 5
- Target Price
- RCKY $30.00
- AARD $33.00
- AVG Volume (30 Days)
- RCKY 68.5K
- AARD 36.8K
- Earning Date
- RCKY 07-29-2025
- AARD 08-14-2025
- Dividend Yield
- RCKY 2.25%
- AARD N/A
- EPS Growth
- RCKY 24.23
- AARD N/A
- EPS
- RCKY 2.48
- AARD N/A
- Revenue
- RCKY $462,328,000.00
- AARD N/A
- Revenue This Year
- RCKY $6.67
- AARD N/A
- Revenue Next Year
- RCKY $4.25
- AARD N/A
- P/E Ratio
- RCKY $11.14
- AARD N/A
- Revenue Growth
- RCKY N/A
- AARD N/A
- 52 Week Low
- RCKY $11.93
- AARD $4.88
- 52 Week High
- RCKY $34.69
- AARD $19.58
- Technical
- Relative Strength Index (RSI)
- RCKY 68.67
- AARD N/A
- Support Level
- RCKY $24.68
- AARD N/A
- Resistance Level
- RCKY $30.90
- AARD N/A
- Average True Range (ATR)
- RCKY 1.41
- AARD 0.00
- MACD
- RCKY 0.32
- AARD 0.00
- Stochastic Oscillator
- RCKY 63.45
- AARD 0.00
About RCKY Rocky Brands Inc.
Rocky Brands Inc acts as a designer, manufacturer, and marketer of premium-quality footwear and apparel. The company's family of brands includes Rocky, Georgia Boot, Durango, Lehigh, Creative Recreation, and the licensed brand Michelin footwear. The company operates its business through three business segments: Wholesale, Retail and Contract Manufacturing. It generates the majority of the revenue from the Wholesale segment.
About AARD Aardvark Therapeutics Inc. Common Stock
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.